Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

被引：0
|
作者：
Gurwitz, David [1 ]
Newman, William [2 ]
机构：
[1] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[2] Univ Manchester, Dept Med Genet, Manchester M13 9PL, Lancs, England
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 18期
关键词：
D O I：
10.1093/jnci/djn269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis
    Chlebowski, Rowan T.
    Col, Nananda
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18): : 1331 - 1332
  • [2] Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer:: A modeling analysis
    Punglia, Rinaa S.
    Burstein, Harold J.
    Winer, Eric P.
    Weeks, Jane C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09): : 642 - 648
  • [3] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis - Response
    Punglia, Rinaa S.
    Burstein, Harold J.
    Winer, Eric P.
    Weeks, Jane C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18): : 1332 - 1333
  • [4] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis - Response
    Hayes, Daniel F.
    Stearns, Vered
    Rae, James
    Flockhart, David
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18) : 1333 - 1334
  • [5] Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and a Validation
    Yu, K-D
    Shao, Z-M
    CANCER RESEARCH, 2010, 70
  • [6] Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation
    Yu, Ke-Da
    Huang, A-Ji
    Shao, Zhi-Ming
    PLOS ONE, 2010, 5 (12):
  • [7] Optimizing adjuvant endocrine therapy for postmenopausal breast cancer: the modified CYP2D6 genotype-based modeling analyses
    Di, G. H.
    Shao, Z. M.
    Yu, K. D.
    EJC SUPPLEMENTS, 2010, 8 (03): : 179 - 179
  • [8] CYP2D6 Genotype Should Not Be Used to Determine Endocrine Therapy in Postmenopausal Breast Cancer Patients
    Rae, J. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 181 - 184
  • [9] Role of CYP2D6 testing in selection of endocrine therapy for breast cancer
    Stebbing, Justin
    Stearns, Vared
    Davidson, Nancy E.
    PHARMACOGENOMICS, 2007, 8 (01) : 1 - 3
  • [10] Commentary: Optimal adjuvant endocrine therapy of postmenopausal breast cancer
    Cunnick, G
    Mokbel, K
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2005, 50 (05): : 197 - 198
12345